3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
46
Phase 2
23
Phase 1/2
18
Phase 3
4
Phase NA
1
Phase 4
1
Phase 2/3
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
109
Gastrointestinal
36
Genitourinary
32
Head & Neck
25
Dermatologic
22
Breast
22
Gynecologic
20
Tumor-Agnostic
4
Sarcoma
3
CNS
3
Plasma cell
2
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Endocrine
1
Conditions
Neoplasms
2
Carcinoma, Squamous Cell
1
Carcinoma
1
Adenocarcinoma
1
Interventions
Carboplatin
8
Paclitaxel
7
Fluorouracil
7
Cisplatin
7
atezolizumab
5
Trastuzumab
5
Pemetrexed
5
Oxaliplatin
5
Leucovorin
5
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Surveys and Questionnaires
3
Observation
3
Leuprolide
3
Irinotecan
3
Glutamine
3
Drug Therapy
3
Docetaxel
3
Dexamethasone
3
130-nm albumin-bound paclitaxel
3
trifluridine tipiracil drug combination
2
regorafenib
2
osimertinib
2
enzalutamide
2
Surgical Procedures, Operative
2
Standard of Care
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
pembrolizumab
×
Tumor-Agnostic
×
Clear all
NCT06901531
2026-06-05
LUCERNA
Astellas Pharma Inc
Phase 3
Recruiting
500 enrolled
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled
NCT03833167
2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3
Completed
450 enrolled
18 charts
NCT03976362
2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3
Completed
851 enrolled
25 charts